Dupixent becomes the first-ever targeted therapy ... driven by the potential savings they are able to deliver to healthcare systems. Web editor Nicole Raleigh speaks with Rob Abbott, CEO and ...

Dermira’s chief development officer Luis Pena said recently he reckons lebrikizumab will be a strong rival to Dupixent thanks ... to healthcare systems. Web editor Nicole Raleigh speaks with ...

“Dupixent is the first new targeted treatment for chronic spontaneous ... Regeneron Forward-Looking Statements and Use of Digital Media Regeneron uses its media and investor relations website and ...

A roundup of health news includes Mexico's first screwworm myiasis case, rising measles cases in Texas, the launch of a new COVID website by Trump's White House, Sanofi-Regeneron's FDA approval for ...

Meanwhile, the Trump administration has criticized the World Health Organization and former top health officials through a newly launched COVID-19 website, while the US FDA limits industry influence ...

Please purchase a subscription to read our premium content. If you have a subscription, please log in or sign up for an account on our website to continue.

Following recent approvals in the EU, US and China, the Singapore approval is based on two replicate phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (“CSU”) in adults and adolescents aged 12 years ...

Sales of its blockbuster asthma drug Dupixent rose 20.3% to 3.48 billion euros, compared with 3.44 billion euros expected on average by analysts. Sales of Beyfortus, a new treatment to protect ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria. The approval is for patients 12 years and ...